Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | LAP3 | P28838 | 6/20 | 0.33 |
| ▸ | ANPEP | P15144 | 4/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211914 | 0.83 | LPAR3 (0.41) | LAP3ANPEPERAP1LPAR3LPAR1 | |
| SCHEMBL11018553 | 0.82 | PPARD (0.34) | PPARDLAP3ANPEPERAP1PLA2G2C | |
| SCHEMBL15726451 | 0.81 | SMN1; SMN2 (0.36) | LAP3LPAR5SMN1; SMN2 | |
| SCHEMBL12873374 | 0.81 | LPAR3 (0.40) | LAP3ANPEPERAP1LPAR3LPAR1 | |
| SCHEMBL17211777 | 0.81 | CYP3A4 (0.40) | LAP3ANPEPERAP1LPAR3LPAR1 | |
| SCHEMBL12212661 | 0.81 | CYP3A4 (0.40) | LAP3ANPEPERAP1LPAR3LPAR1 | |
| SCHEMBL12212669 | 0.81 | LPAR3 (0.50) | LAP3ANPEPLPAR3LPAR1LPAR2 | |
| SCHEMBL12212668 | 0.81 | LPAR3 (0.50) | LAP3ANPEPLPAR3LPAR1LPAR2 | |
| SCHEMBL12212674 | 0.81 | CYP3A4 (0.40) | LAP3ANPEPERAP1LPAR3LPAR1 | |
| SCHEMBL17211778 | 0.81 | CYP3A4 (0.40) | LAP3ANPEPERAP1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | PPARD 1308/4885LAP3 478/4885ANPEP 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.